LOL

Page II item 4. = our new controller

http://www.sec.gov/litigation/complaints/2008/comp20645_sniffex.pdf

I love getting in before the pump :)

A total of 2,090,044 shares of our common stock outstanding are considered to be outstanding pursuant to SEC Rule 13d-3(d)(1) as of September 27, 2010. For each beneficial owner above, any options exercisable within 60 days have been included in the denominator.


As of September 27, 2010, there were 48 holders of record of our common stock.


As a result of the closing of the Purchase Agreement and the Repurchase Agreement, the Investor under the Purchase Agreement now holds 63.79% of the Company’s outstanding capital stock resulting in a change in control of the Company.


Shares are held in the name of Helvetic Capital Ventures AG. Helvetic is based in Switzerland and operates primarily in Europe but invests heavily in foreign and U.S. based companies. Ilona Klausgaard is the president of Helvetic. Although she is not a majority owner of the company she makes all of their investments decisions and has the authority to vote on a majority of our shares. Under Swiss law, the shares of Helvetic are traded in bearer form. Helvetic issues dividends to its shareholders once per year but their bearer shares could trade many times without the company’s knowledge during the year. Until shares are presented for dividends, Helvetic has no way of knowing who owns their stock. As of the last dividend calculation, Dr. Urs Felder was the sole shareholder of Helvetic as set forth in our Annual Report on Form 10-K for the year ending June 30, 2010.


? http://www.moneyhouse.ch/en/u/helvetic_capital_ventures_ag_CH-320.3.059.052-2.htm ?

No & I am scratching my head. I looks to me that it's business as usual & CEO just gave up control & paid off all the debt. WTF?

!!!!!!!!!!!10K OUT!!!!!!!!!!!
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7491951

still climbing on average volume. looking good here
I think investors are getting wind of the Blackstone potential
I love it

couple of things:
council confirmed, CBIS officers are not posting here.

I see some credable press that draws a conclusion;
Gov. Arnolds passing of the recent law reducing penaties
is an attempt to undermine prop19

pump, I told you so: as soon as you start asking tough questions, communication will stop.

I think your on
Steve wont give up majority, any dilution will also be met with inside distribution. That inside distribution will happen at the low. I think we lived it or are living it

Steve wants to uplist this shipwreck & that cant happen down here

That press release is the start, it has been my experience (or speculative theory) that companies buy publicly releases packages; like buy 6 get 3 free of a bakers dozen.....I think more & bigger & better are coming. They just increased the AS by 400%. and they are late on this filing ... something is cooking

I think /pray/ we are headed back to dollar land

GO ECOB! We are going to blue skys here by EOY - IMO
fasten your belt and set your limits!

Business Description
Spur Ranch will introduce the elite and intriguingly elusive sport of polo to an entirely new audience. Traditionally a sport catering to high society, the 400 year old "sport of kings" will now be presented to a whole new demographic via intelligent development and strategic marketing. The Company plan focuses on developing equestrian and polo themed communities and venues, with its operations firmly grounded in real assets. The Company intends to profit from developing these unique communities, operating equestrian facilities, merchandising and promoting sponsorships of its facilities and events. Headquartered in Austin, Texas with a domestic and international focus on spreading the adoption and spectatorship of polo and other equestrian eventing, Spur Ranch will also produce entertainment media that will bring the equestrian lifestyle into the living rooms of the world.

Spur Ranch has four principal revenue segments. 1) polo and equestrian themed real estate development 2) "reality-based" television programming 3) Equestrian facility development and Operations and 4) Polo and equestrian tournaments and sponsorships.

Spur Ranch will give new life to a sport that has stood the test of time while offering a lifestyle that, before now, was thought to be strictly reserved for society's elite. The dawn of a new era, Spur Ranch will introduce luxury and regalness into any home, regardless of income.

so lets speculate & think out loud; CBIS has claimed organic grow operations in Colorado.
We are hopeful for running operations soon with the SFIO joint venture poising us for a profitable venture that will capitalize on the november ballot.

How will CBIS get product from Colorado to California?
Do you think we will see news of a DBA or new LLC affording CBIS to cultivate in California?

That is a great story and a great outcome. Good on you dr bob. I would love to know more; is CBIS still active in this case? Does CBIS sponsor special need cases? That is a moving story....bless that Mother

I have stated; I believe prop19 is instramental & needed for border reform. Demand will be met with supply from this side of the fence. Prices along the border are allready at an all time low; I have knowledge of 200$ lbs. Soon the trafficing of Mexican herb & enforcment will be mute. imported weed will be so substandard it will not have a place in the market. Bordering states / 420 prohibited / will profit greatly as they capture traffic and penalize with fees.

I hadn't research the sfio jv very much but if cbis can get product to sfio and if sfio can package and distribute maybe it will be profitable...but I question how much $ roockbrook will eatup, if any.
Sfio seems to be the only connection cbis has in ca.
I am hopefull for at least a fluff pr cbis / sfio / jv run

Ice; your DEA salary speculation is way out of line.
respectfully.

http://www.legal-criminal-justice-schools.com/Criminal-Justice-Degrees/DEA-Agent.html

http://www.fedsmith.com/pay_rates/

Yeah, i remember you schooled me on that. I wonder why otcmarkets tab says short sales though shouldn't it say short interest?

The new layout of otcmarkets.com has a tab for short interest, makes checking short interest easier- imo

http://www.otcmarkets.com/stock/CBIS/short-sales

Anyone check out the CBIS Forum

http://forum.cannabisscience.com/viewforum.php?f=26&sid=858fb7db27dd8cc9f7ace579384218b6

Seriously; they should clean that up. crusty Nike spam.
If someone here speaks with anyone at CBIS next week please ask them to clean the forums/threads

Thats all good but I would rather have chicken tenders than a kitten for my dividend.

Pump your being silly; a paid basher. I have been truthful and honest and my intentions in discovery are not malicious they are for seeking what is going on and what has been going on with our publicly held comany. I have asked real good questions and left real voice mails and emails for the company and they have al gone unanswered. No big deal, the future is unavoidable. I believe we are a very small percentage of the CBIS shareholders but we appear to be the most vocal. You should embrace my skepticism and consider it for what it is worth; just another shareholders opinion. I will hold and wait and see what comes next....I think kittens....kittens will come next. They will pay us our dividend in cute fluffy kittens...LOL

World Equestrian Games on the boob tube now!!!!!!
Go Spur Ranch
Go Mr Stack & Co.

I recently asked Andrew if Spur Ranch would rep @ the W.E.G.
they are very tight lipped; he replied to keep any eye out for exciting filings....

DJH, I worked with 'the group', I am not a consultant. I have smoked but do not now and haven't for a long while. My work affords me the ability to brush shoulders with unbelievable hierarchy and some days I get my toes stepped on by janitors. This conversation regarding Prop19, public MJ companies & being high came up over dinner and it was an in jest comment. I capitalized on the comment; it is nice to know your friends/coworkers/colleges point of view on tabu topics (imo), It can save embarrassment and maybe afford you the ability to make an outsider feel welcomed in confirmation or conversation. In this case I wanted eagerly to know the group of Californians opinion on Prop19.

Re; SFIO and our CBIS joint venture. I have stated previously
The possible ability to deliver an exact dose is a benefit
The prepackage for the handicap is a benefit
and I came up with a few other pluses
but that was before the Rockbrook deal devolved.

With Rockbrook having full latitude over and within CBIS product now, is the SFIO joint venture filtered via Rockbrook? Will Rockbrook have claim to CBIS / SFIO revenue?

I worked with a group of consultants last week, they traversed in from San Diego.

I waited and waited; finally one of them mentioned Pot or getting high. It was cue; I casually quizzed the group and found that that everyone of them believed that prop19 will pass. Their view(s) paralleled mine on the supply and demand and factored it will pass as a mater of border security. Being that, americans thirst for MJ will now be quenched with Made In The USA Marijuana.
just thought i'd share....
I haven't spent much time looking into SFIO; maybe it will be the CBIS lifeline

I hope so.

Maybe I will take a vacation from CBIS and go fire up the SFIO board....you guys are getting moody :)

topdog52: I have asked many questions here and they all go unanswered. I'm not a 'basher'.
I Im a common share holder and want nothing but the best for cbis.


You seem excited for cbis with the upcoming ballot. How will CBIS prosper in regards to the California Ballot?

SFIO has an existing contract with the military?
that sounds great...
would you please link some intelligence regarding that SFIO - GSA contract, please?

summary of the past 15 months of operations news. (35 releases I've concluded)
I disregarded and skipped over our companies statements of market conditions, filings, comments regarding other companies or other countries, and fluff.

Below this almost totally reads like a book of fiction - imo

6/18/2009….cbis…announced today that patent filings are expected for two of its key innovations. The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two, Dr. Mary J. Ruwart, Vice President, Research & Development explained. A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to invasion by a competing company

7/02/2009…cbis...is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.

7/17/2009…cbis…is moving forward confidently under the guidance of its new President & CEO, Dr. Robert Melamede Ph.D. The planning for the companys product line up remains the same, including its FDA fast track initiatives. In the light of recent corporate management changes, Dr. Melamede has begun negotiating with high level industry executives to build a new team with both FDA protocol and research experience to work on Cannabis Sciences extensive product line up and rapid market entry initiatives

7/20/2009….cbis….is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs.
As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.

7/24/2009…cbis…is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming……The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response.

7/27/2009…cbis…to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medici

7/28/2009…cbis…the FDA has provided the Company with documentation to assist the Company to review and plan its initial applications to get its first drug into formal testing.

8/12/2009…cbis…has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time…..The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the www.cannabisscience.com website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.

8/31/2009….cbis….has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

9/21/2009…cbis…is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.Robert Melamede stated, “After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge.” Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.

12/02/2009…cbis…it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares…

12/15/2009…cbis…it has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The Company is producing 10-15 different public service announcements in the series. Each one will cover a different topic, such as new break-through research developments, and tracking current and future cannabis medicines going through the FDA process. As well, the series will cover the commercialization of medical marijuana through licensed dispensaries, plus patient interviews about cannabis uses and life experiences, government legal issues and legalization progress tracking, as well as interviews with Doctors, patients, law makers and activists.

1/11/2010…cbis…is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."……On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.

1/25/2010…cbis….released updates to its website today. The website www.cannabisscience.com now integrates its general public communications with recent and future developments in its analytical lab work, clinical research, and commercial production division that are in the process of formalizing the agreements with all the necessary contractors in order to move forward with its medical cannabis clinical trails…….The updated website includes new tools that allow its analytical, clinical research, and commercial production divisions to communicate with the medical cannabis community, survey specific populations, and receive feedback from patients, partners, and investors. The information gathered through its site surveys and forums will help guide its clinical research as well as contribute to scientific databases, and our live blog will allow the community to check in on its progress.

2/09/2010….cbis….it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market….Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.

2/22/2010….cbis….progress in its Analytical Lab Division at Cannabis Science. Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., explained, " As a patient oriented company located in a state with effective medical marijuana laws, we are able to study the medical production and use of cannabis in a variety of modalities. At the core of this research, we are working with patients producing top grade medical cannabis as the starting point for extracts and formulations to treat the many disease states that cannabinoids positively impact. Efficient, stable propagation and quality control of the starting material and downstream processes are essential to this progress."There are several integral and interdependent facets of this approach: Lab Division:I. Propagationa. Traditional Cloning, Micropropagation & Extensive Seed BankII. QC & Analyticsa. Genetic QC such as Fingerprintingb. Biochemical & Contaminant QC including HPLC and GCIII. Extracts and FormulationsIV. Final Product Testing a. Local clinical Trials b. FDA Clinical Trials

2/25/2010…cbis….is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.

5/7/2010….cbis….has opened an in-house investor relations and public relations department in South Florida.  Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start.  Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.

5/12/2010….cbis….it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system.

5/13/2009…cbis…it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines….Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders.  Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."

5/24/2010…cbis….it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.

6/01/2010…cbis…is pleased to announces preliminary patent disclosures and major steps towards the acquisition of a private company for the development of the new patentable products that should facilitate broad acceptance of specific Cannabis Science pharmaceutical products designed for the treatment of chronic pain, Post Traumatic Stress Disorder (PTSD) and other critical illnesses addressed throughout the www.cannabisscience.com company website….Melamede, PhD., Cannabis Science President and CEO, reported, "We have been negotiating to purchase a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. As a faculty member at the University of Colorado at Colorado Springs, I have filed a preliminary patent disclosure with the University of Colorado regarding additional new technology that Cannabis Science intends to develop through the targeted private company acquisition. As a part of this process, we are hiring a distinguished patent attorney to help with the University disclosure and ultimate patent filings. We are also using our FDA consultants to advise on the technology's FDA approval pathway because we foresee several new FDA pharmaceutical products that can be derived from this deal."

6/17/2010…cbis….is pleased to report that it is acquiring one of the leading medical marijuana providers and pioneers in the industry in the state of Montana; Montana Pain Management, Inc. (MPM) (http://www.montanapm.com). MPM is a for-profit clinic which, in conjunction with duly licensed caregivers, provides a full range of cannabis therapeutics and other services to its patients throughout the state of Montana

6/29/2010….cbis….reports that it has begun the process of expanding the internal production and research capabilities of Missoula medical cannabis provider, Montana Pain Management (MPM), which Cannabis Science acquired earlier this month.

7/06/2010….cbis….is proud to announce that Dr. Arturo Morales of Hartford, Connecticut, has agreed to join its Scientific Advisory Board. Dr. Robert Melamede PhD., Cannabis Science President and CEO noted, "We are extremely honored to have such a distinguished doctor join our Scientific Advisory Board. Dr. Morales has said that he wishes to become a 'successful advocate in the struggle to remove restrictions on the medical uses of cannabis.' We are delighted to welcome him to our team.

7/08/2010….cbis….it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.

8/12/2010….cbis….announced today that it has executed a Joint Venture Agreement with Smokefree Innotec Inc. (Pink Sheets:SFIO). The objective of the joint venture is to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products. Under the joint venture, Smokefree Innotec, Inc. will provide its high-tech smoke-free vapor technology devices, and Cannabis Science will provide all the medical cannabis extract formulations. Both parties equally share in the revenues derived from this Joint Venture.

8/18/2010….cbis….reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement that he and Montana Pain Management, Inc. ("MPM") had signed with Cannabis Science. Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, "We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse.

8/18/2010….cbis….signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

8/18/2010…cbis….Thomas Schroepfer, CEO, (http://www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, “Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations.”

8/24/2010….cbis….Dr. Robert Melamede, PhD., whose mother was German, remarked, "Germany's recognition of the medical value of cannabis coincides with our plans for expansion into Europe.  We hope that America is not going to squander its lead in medical cannabis research, but Cannabis Science will certainly work with German and other European researchers and clinicians to develop medical cannabis products that meet the needs of patients around the world."

8/30/2010…cbis….is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges…..cbis…..is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex® in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex® is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.

9/09/2010….cbis….is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.

9/13/2010…cbis….announces the formation of a new LLC, CANNABIS SCIENCE SMOKEFREE JV LLC, which has started testing various medical cannabis formulations for possible early JV product release entering the potential multi-billion medical cannabis market.

9/20/2010….cbis….is pleased to announce that its Board of Directors have begun investigating the corporate and legal requirements required to issue dividends to shareholders to create a new class of common shares. …..The company is in advanced negotiations with several groups pursuing funding opportunities for up to $5 million between $1.00 and $3.00 per new share. ……The proceeds will be used to fund FDA clinical trials, acquisitions, and further product research and development.

DSU: thanks have a nice weekend

Like post 6267?

And the Share structure is nice - IMO
The investor has majority interest and plenty of shares to solicit

Got that PM; I have a fan club as well :)

I called PNXE about 30-60 days ago and got a tight lipped receptionist
never got a call back, but, all that is water under the bridge now
I held.

from what I can tell the bills are paid and pnxe is now a shell
the investor paid about 13 bucks a share / just over 100K
what i don't understand is this strategy:

On September 23, 2010, Phoenix Energy Resource Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) between the Company, Helvetic Capital Ventures AG (“Helvetic”) and the accredited investor signatory thereto (the “Investor”), pursuant to which, the Company sold an aggregate of 1,333,336 shares (the “Shares”) of the Company’s common stock par value, $.001 (the “Common Stock”) to the Investor for an aggregate purchase price of $100,103. Simultaneously with the closing of the Purchase Agreement, the Company repurchased 1,333,336 shares of common stock held by Helvetic, for an aggregate purchase price of $100,103, net any outstanding liabilities of the Company as of the closing date, as contemplated by a repurchase agreement, dated September 23, 2010, by and between the Company and Helvetic (the “Repurchase Agreement”).

I'm interpreting that as Helvetic has an interest and is comfortable
with the chinese investor controlling

it might be OT: but I read a report last night about a surplus amount of chinese IPO's that were going to be hitting the market. Im hoping for something hot & spicy like kung pow chicken here :)
this is exciting - imo

I briefly read thru the bulletin board section/link and found that Dr. M
is planning on / hopefully going to be working with the fugitive on a cannabis oil product
They are attempting to patten and trademark names and products
and create a method of exact doses. It may be promising....
I hope so.

Has anyone heard more news about the dividends?

Anyone else holding???

That is alarming you should email Mr. Quick with your concerns
i have found him to be very responsive and available
please share his responce to your accusation.

What specifics lead you to believe this is a D&P?

My research regarding mppc shows a company with a storefront that holds normal hours, employees, and (unheard of for a OTC/pink) revenue & profit
Mppc maintains officers that have brand name identification
also this company is coupled with great partnerships that are fruit bearing

respectfully,
dade

were sold: the resignation and release of the sole officer and director of the Company, such resignation to be automatically effective on the tenth day following the mailing of an information statement on Schedule 14f-1 to the Company’s stockholders announcing a change of control in connection with the Company’s planned reverse acquisition of an offshore operating company, and the designees, if any, specified by the Investor will have been appointed as officers and directors of the Company;

OMFG! The guy is a fugitive & criminal of course CBIS will be doing business with him shortly. LOL

Money in the bank

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7477071

(i) The Company’s authorized capital stock, as of the date of this Agreement, consists of 100,000,000 shares of Common Stock, $0.001 par value per share, of which 2,090,044 shares are issued and outstanding, and 5,000,000 shares of Preferred Stock, $0.001 par value per share, of which no shares are issued and outstanding.

So those pictures are somewhat promising that competent people are in the field.
They have set up shop and are poised to grow something in that ginormous bioreactor....

But I have an operational question....

So they grow whatthefockever
this time the bioreactor doesn't burst, leak, or fall apart

1.then what?
they send it to Guam in 55 gallon drums to have ladies
run it though cheese cloth and pound algae clots between rocks?

2. Have we seen an extraction process other than leaks or bursting equipment?
Is BEHL able to harvest and prepare the whatthefockever for market?

3. Is "the market" in cue?

Rozzy; I'm not an investment consultant
I'm a share holder sitting on a loss that continues to nose dive
and no one knows why.....

I'm hoping some one like an officer of cbis proves
me to be foolish here....
But I think my compaintS will bring some attention and lightFor us soon

I did send it to the company; the info@ & cowans & marks email.
Still no answer: I think they are hiding the fact that the big picture
is drawn on a dry erase board in dr bobs condo - IMO

Still no answer? I wonder why?

I would like to purchase more common stock, averaging down on my substantially negative equity position with Cannabis Science 
but before I do that, I would greatly appreciate a response to these simple questions regarding our publicly traded comany

Because of the sensitivity of some of these questions and to protect my interest I have blind carbon copied my council
and have poised these questions to the trading public on an open forum.
Your timely response either private or public will be appreciated. 

Questions for CBIS Officers:


1. Does CBIS have any intent or plan of action for capitalizing on California's upcoming Proposition19 vote should it pass as expected?
if so, please describe in specifics.
If not why have you ignored this market;  California has paved the way to greatness with it's unofficial most profitable & largest export (ahead of even wine, women and song) being Marijuana. CBIS officers have claimed to be industry leaders with massive foresight and industry knowledge. Please explain why we are not poised within California.

2. In June of 2010 CBIS publicly released the acquisition of Montana Pain Management.  Two months later you publicly released that CBIS would pursue legal action against Mr. Rosio for deliberately breaching a non disclosure/non-circumvention agreement. 
Have you exhausted this pursuit?
Does Dr. Morales have any interest with CBIS?
Does Mr. Rosio have any interest with CBIS?

3. On feb. 18, 2010, The Vancouver Sun Reported:   Banned promoter (Ray Dabney) may soon be back touting penny stocks
Read more: http://www.vancouversun.com/life/Banned+promoter+soon+back+touting+penny+stocks/2579722/story.html#ixzz10n0ZamGq

Is this the same Ray Dabney that Richard Cowan admits to receiving equity / stock advise from?
Is Ray Dabney involved with CBIS? 
If so in what capacity? 

4. On July 8, 2010 CBIS publicly released the "Acquisition of New 9,500 Square foot Denver facility for researching, Developing, Testing and Producing Medical Cannabis. Since that release shareholders have not received an update regarding this space.
Has CBIS executed a lease or purchase agreement?
If so please offer further details regarding this space, its condition, and if or if not CBIS is operating or improving this space for operations. 
Specifics here would be welcomed regarding this as shareholders have sent numerous inquiries that have gone unanswered.

5. A shareholder has recently calculated that CBIS has swapped some 33,888,295 shares of common stock between Aug of 2009 and May 19, 2010
How many shares of common stock has CBIS issued in the period from May 19, 2010 to our current date?
Do the officers of CBIS foresee sustainability at any point, from revenues or profit or activities other than the issuing of shares, that will relief the issuing and dilution of our common stock?

6. Because of the transfer of Title, Ticker, Ownership, and cusip: It is difficult to conclude who or what entity maintains majority interest. 
It is assumed that K&D Equity maintains majority interest. 
Please clarify; 
Who (or what combined group) maintains majority interest in CBIS?

7. On Aug 18, 2010 multiple statements were released by CBIS
A. regarding Rockbrook: Please describe our current working relationship and operations and wether officers are pleased with the agreement that was reached. 
Has Rockbrook produced funds per the agreement?
Do we expect to continue our relationship with Rockbrook? 
B. regarding Smokefree Innotec: It was publicly released that CBIS was entering into a joint venture agreement with SFIO to develop and market smoke free vaporized medical cannabis pharmaceutical products. 
Has the Joint Venture been executed? If so what are the basic terms 
Has any progress been made with these smoke free vaporized medical cannabis pharmaceutical products?
If so to what extent?

Thank you for your time and service 
The shareholders and Trading Public on our Open Forum are excited for you response.

Respectfully, 

Hey pump did you check out the replys to this article?

http://www.independentpoliticalreport.com/2010/06/court-judgment-kubby-regains-control-of-cannex-therapeutics/

I know it isn't as fresh as your breakout prediction but the posters seem to know what they are talking about;
what do think?


I have been sitting by the side lines on this for a while now but in light of today’s press release, June 15th, 2010, I think that some light needs to be put on this situation.

Richard Cowan in the press release states that Steve Kubby was fired “because of his questionable financial activities and his apparent inability to understand the basics of corporate governance for a public company.”

I wonder if mister Cowan is aware of is inability to understand the basics of law. On June 8th’s decision ruling by U.S. district judge Richard A. Schell said “The Purchase Agreement and Control Shareholder Agreements are rescinded and cancelled, nunc pro tunc to the dates of execution for any and all purposes.”

Nunc Pro Tunc as defined means Now for then. In general, a court ruling “nunc pro tunc” applies retroactively to correct an earlier ruling or descision.

In this case it means this agreement never existed.

Now if we look at this as the whole picture. Cannex (Steve Kubby) had the deal with K & D (Charlie Stidham) for the shell based on the now nunc pro tunc agreement. I didn’t see Cowan or Melamede in this agreement or ruling, so since the original deal is nunc pro tunc, Cannabis Science is, in theory, non-existant! The only reason these guys are able to keep the doors open and the lights on is that Mr. Stidham is allowing them to continue. That is probably for two reasons only. His vested interest in the shell and he doesn’t want hundreds of share holders raining on his parade.

As for the quote in the press release from Charlie Stidham saying “To see them build the company this quickly having so many opportunities by far overshadows over any single lozenge, which now is obviously just a minimal part of the Cannabis Science big picture.”

How have they built the company this quickly? What have they really done except dilute the stock like crazy. Where is the big picture? At least with the lozenge there was possible Worldwide distribution, corporate buyout possiblities where the shareholders would win big and a defined purpose. Not to mention and the reason I became interested was a possible cure to many illnesses in a proper delivery form.

Need I remind everyone that medical cannabis is still federally illegal and could cause some difficulties in the industry and the future of CBIS in the days to come. That is being proven with many of the California dispensaries being raided and closed down. At least with the lozenge they were suppose to go for FDA approval and human trials which once proven and approved would be unstoppable. $$$

As I see it now, Cannabis Science is nothing more than a smoke and mirrors show to help pay some corporate wannabes a yearly salary.
Until they really show us otherwise, how can we believe anything they say?

Show us the “BIG PICTURE”!

NOTIFICATION OF LATE FILING

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on

[ X ] or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or subject distribution report on
Form 10-D, or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7477954